Viruses change quickly, as the Covid-19 coronavirus has reminded the world. In order to develop new drugs rapidly, “platform technology” is an essential tool for biopharmaceutical companies.
CHA Vaccine Institute, the Korean vaccine maker, finished its first day of trading up 18.2 percent from its offering price of 11,000 won ($9.30).
CHA Vaccine Institute hopes to be the world’s first bio company to release therapeutic vaccine for chronic hepatitis B.
CHA Vaccine Institute submitted a securities registration statement to the Financial Supervisory Service, the vaccine maker said Tuesday.
CHA Vaccine Institute, a vaccine maker that is 46 percent owned by CHA Biotech, is a step closer to going public as its application passed a preliminary screening by the Korea Exchange.
Korea JoongAng Daily Sitemap
